JP2019529385A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529385A5
JP2019529385A5 JP2019512292A JP2019512292A JP2019529385A5 JP 2019529385 A5 JP2019529385 A5 JP 2019529385A5 JP 2019512292 A JP2019512292 A JP 2019512292A JP 2019512292 A JP2019512292 A JP 2019512292A JP 2019529385 A5 JP2019529385 A5 JP 2019529385A5
Authority
JP
Japan
Prior art keywords
use according
mammal
cells
cns
therapeutic protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529385A (ja
JP7610923B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/049959 external-priority patent/WO2018045347A1/en
Publication of JP2019529385A publication Critical patent/JP2019529385A/ja
Publication of JP2019529385A5 publication Critical patent/JP2019529385A5/ja
Priority to JP2022002163A priority Critical patent/JP2022050574A/ja
Application granted granted Critical
Publication of JP7610923B2 publication Critical patent/JP7610923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512292A 2016-09-02 2017-09-01 Cns障害を治療するための方法及びベクター Active JP7610923B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022002163A JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383274P 2016-09-02 2016-09-02
US62/383,274 2016-09-02
PCT/US2017/049959 WO2018045347A1 (en) 2016-09-02 2017-09-01 Methods and vectors for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022002163A Division JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Publications (3)

Publication Number Publication Date
JP2019529385A JP2019529385A (ja) 2019-10-17
JP2019529385A5 true JP2019529385A5 (enExample) 2020-09-17
JP7610923B2 JP7610923B2 (ja) 2025-01-09

Family

ID=61309371

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019512292A Active JP7610923B2 (ja) 2016-09-02 2017-09-01 Cns障害を治療するための方法及びベクター
JP2022002163A Pending JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022002163A Pending JP2022050574A (ja) 2016-09-02 2022-01-11 Cns障害を治療するための方法及びベクター

Country Status (9)

Country Link
US (1) US20190192693A1 (enExample)
EP (1) EP3506930A4 (enExample)
JP (2) JP7610923B2 (enExample)
CN (1) CN110121356A (enExample)
AU (2) AU2017318717B2 (enExample)
BR (1) BR112019004353A2 (enExample)
CA (1) CA3035628A1 (enExample)
MX (1) MX2019002518A (enExample)
WO (1) WO2018045347A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
CA3069880A1 (en) * 2017-07-17 2019-01-24 Spark Therapeutics, Inc. Apheresis methods and uses
IL279131B2 (en) * 2018-06-28 2025-06-01 Univ North Carolina Chapel Hill Optimized cln5 genes and expression cassettes and their use
SG11202103102WA (en) 2018-09-26 2021-04-29 California Inst Of Techn Adeno-associated virus compositions for targeted gene therapy
BR112021006060A2 (pt) 2018-10-01 2021-07-20 The Trustees Of The University Of Pennsylvania composições úteis para tratamento de gangliosidose gm1
IL327339A (en) * 2018-11-14 2026-05-01 Regenxbio Inc Gene therapy for neural ceroid lipofuscinosis
BR112021010234A2 (pt) * 2018-11-28 2021-08-24 Prevail Therapeutics, Inc. Terapias de gene para doença neurodegenerativa
MX2021010134A (es) 2019-02-22 2021-09-23 Univ Pennsylvania Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn.
WO2021061909A1 (en) * 2019-09-24 2021-04-01 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Method of targeting neuronal apoe to treat a neurocognitive disorder
US20230405148A1 (en) * 2019-10-16 2023-12-21 Cornell University Gene therapy for alzheimer's disease
IL293116A (en) 2019-11-25 2022-07-01 Univ Cornell apoe gene therapy
US20230384310A1 (en) * 2020-10-01 2023-11-30 Sangamo Therapeutics, Inc. Methods of detecting anti-aav antibodies
CN112852881B (zh) * 2021-02-09 2023-08-15 南京贝思奥生物科技有限公司 利用细胞穿膜肽增强腺相关病毒在中枢神经系统转导效率的方法
TW202426479A (zh) * 2022-10-10 2024-07-01 美商星火治療公司 Apoe基因療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
CN107828820B (zh) * 2010-10-27 2022-06-07 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
EP2850195B1 (en) * 2012-05-18 2020-01-22 University of Iowa Research Foundation Methods and compositions for treating amyloid deposits
PT3024497T (pt) * 2013-07-26 2021-08-23 Univ Iowa Res Found Métodos e composições para o tratamento de doenças cerebrais
IL245703B (en) * 2013-11-20 2022-07-01 Univ Iowa Res Found Methods and compositions for treating amyloid deposits
CN108347932B (zh) * 2015-02-20 2022-09-13 衣阿华大学研究基金会 用于治疗遗传性眼病的方法和组合物

Similar Documents

Publication Publication Date Title
JP2022508182A5 (enExample)
ES2897508T3 (es) Variantes de virus adenoasociados y métodos de uso de las mismas
JP2020527333A5 (enExample)
ES2903127T3 (es) Terapia génica para trastornos neurodegenerativos
JP2022549140A5 (enExample)
JP2016503405A5 (enExample)
JP2021511803A5 (enExample)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
HRP20192141T1 (hr) Genska terapija za retinitis pigmentosa
JP2017509632A5 (enExample)
JP2022551744A5 (enExample)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
JP2020519629A5 (enExample)
JP2017529395A5 (enExample)
JP7616668B2 (ja) Ube3a遺伝子および発現カセットならびにそれらの使用
CA3158518A1 (en) Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases
JP2020509786A5 (enExample)
IL292264B1 (en) Aav transfer cassette
JP2021520811A5 (enExample)
JP2023520763A5 (enExample)
CN114144518A (zh) 用于基因疗法的双亮氨酸拉链激酶抑制剂
JP2023515795A5 (enExample)
JP2024515902A5 (enExample)
HRP20220199T1 (hr) Postupak genetskog liječenja korištenjem virusa aav-xbp1s/gfp i njegova uporaba u prevenciji i liječenju amiotrofične lateralne skleroze
US12516301B2 (en) Optimized SUMF1 genes and expression cassettes and their use